^
    Back
    Association details:
    Biomarker:BRAF V600K
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.

    Published date:
    05/19/2021
    Excerpt:
    We systematically evaluated all melanoma patients who started adjuvant PD-1 antibody therapy...Patients with BRAF V600E/K mutation and TMB high had the best outcome….
    DOI:
    10.1200/JCO.2021.39.15_suppl.9524